Physician profile
Ralph C Goodman
NPI 1497718795
$411,461.89
in general payments reported to CMS, 2019-2025
20 companies · $49K in 2025
The $49K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105K · 2020: $47K · 2021: $19K · 2022: $90K · 2023: $56K · 2024: $44K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $131K · Travel and Lodging: $14K · Food and Beverage: $4,583 · Education: $19.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,550.00 |
| Travel and Lodging | $13,944.26 |
| Food and Beverage | $4,582.63 |
| Education | $19.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $407,057.56 | 2019-2025 | Mounjaro, Jardiance |
| Abbvie INC. | $2,685.69 | 2019 | |
| Amgen INC. | $316.08 | 2019-2024 | Tepezza |
| Radius Health, INC. | $267.34 | 2019 | |
| Merck Sharp & Dohme LLC | $170.81 | 2019 | |
| Novo Nordisk INC | $116.12 | 2022-2024 | Ozempic, Rybelsus |
| Medtronic Minimed, INC. | $99.96 | 2020 | |
| Dexcom, INC. | $99.64 | 2019-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $94.48 | 2021-2024 | Minimed 780g |
| Insulet Corporation | $88.62 | 2019-2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.54 | 2019-2023 | Jardiance |
| Abbott Laboratories | $81.27 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $64.35 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $59.38 | 2019 | |
| Tandem Diabetes Care, INC. | $49.12 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $39.48 | 2021-2023 | Tepezza |
| Shire North American Group INC | $35.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.81 | 2023 | |
| Beta Bionics, INC. | $18.09 | 2024 | Ilet Bionic Pancreas |
| Nevro Corp. | $14.46 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.